Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Melanoma 2

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × keyhole-limpet hemocyanin × Dermatologic × Clear all
NCT00124124 2015-02-13

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Bhardwaj, Nina, M.D.

Phase 1 Completed
50 enrolled
Dermatologic

Melanoma

NCT00091143 2013-04-04

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡